NovoTTF™-100A System (Tumor Treating Fields) transducer array layout planning for glioblastoma: a NovoTAL™ system user study

World Journal of Surgical Oncology

Research

Uri Weinberg¹  Aafia Chaudhry²  Laura Benson²  Ori Farber³  Yoram Palti³  Eilon Kirson³  Michael Varshaver⁴ 

[1] Clinical Development, Novocure Ltd., Park 6, CH-6039 Root D4, Lucerne, Switzerland;Medical Affairs, Novocure Ltd., New York, NY, USA;Research and Development, Novocure Ltd., PO Box 15022, Topaz Building, 4th Floor, MATAM Center, Sha’ar HaCarmel, Haifa, Israel;Technical Operations, Novocure Ltd., 195 Commerce Way, Portsmouth, NH, USA;

关键词: Glioblastoma;    Optune;    NovoTAL System;    NovoTTF-100A System;    Tumor Treating Fields;    TTFields;   

DOI  :  10.1186/s12957-015-0722-3

 received in 2015-05-28, accepted in 2015-10-26,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundOptune™, previously known as the NovoTTF-100A System™, generates Tumor Treating Fields (TTFields), an effective anti-mitotic therapy for glioblastoma. The system delivers intermediate frequency, alternating electric fields to the supratentorial brain. Patient therapy is personalized by configuring transducer array layout placement on the scalp to the tumor site using MRI measurements and the NovoTAL System. Transducer array layout mapping optimizes therapy by maximizing electric field intensity to the tumor site. This study evaluated physician performance in conducting transducer array layout mapping using the NovoTAL System compared with mapping performed by the Novocure in-house clinical team.MethodsFourteen physicians (7 neuro-oncologists, 4 medical oncologists, and 3 neurosurgeons) evaluated five blinded cases of recurrent glioblastoma and performed head size and tumor location measurements using a standard Digital Imaging and Communications in Medicine reader. Concordance with Novocure measurement and intra- and inter-rater reliability were assessed using relevant correlation coefficients. The study criterion for success was a concordance correlation coefficient (CCC) >0.80.ResultsCCC for each physician versus Novocure on 20 MRI measurements was 0.96 (standard deviation, SD ± 0.03, range 0.90–1.00), indicating very high agreement between the two groups. Intra- and inter-rater reliability correlation coefficients were similarly high: 0.83 (SD ±0.15, range 0.54–1.00) and 0.80 (SD ±0.18, range 0.48–1.00), respectively.ConclusionsThis user study demonstrated an excellent level of concordance between prescribing physicians and Novocure in-house clinical teams in performing transducer array layout planning. Intra-rater reliability was very high, indicating reproducible performance. Physicians prescribing TTFields, when trained on the NovoTAL System, can independently perform transducer array layout mapping required for the initiation and maintenance of patients on TTFields therapy.

【 授权许可】

CC BY   
© Chaudhry et al. 2015